Monoclonal antibodies that target the epidermal growth factor receptor (EGFR) are an approved targeted therapy for chemotherapy refractory CRC patients that do not harbor mutations in KRAS [62,63]. The gene discussed is EGFR; the disease is colorectal carcinoma.